Windsor Regional Hospital Approved To Provide COVID-19 Monoclonal Antibody And Anti-Viral Medication
Windsor Regional Hospital has been approved to provide COVID-19 medications of monoclonal antibody and anti-viral medication to treat COVID-19 for positive patients who meet very specific criteria established by the Ontario COVID-19 Science Advisory Table.
Paxlovid is a pill form anti-vital treatment for high risk patients with mild to moderate COVID-19 symptoms, while Sotrovimab is an antibody infusion (IV) treatment for COVID-19 patients with mild to moderate COVID-19 symptoms. Both are among the treatments that have been approved by Health Canada. There is currently a limited supply of both medications.
If you fall under any of the categories below you may qualify for either Monoclonal Antibody Treatment or Antiviral Treatment for Covid-19:
- immunocompromised individuals aged 18 and over regardless of vaccine status
- unvaccinated individuals aged 60 and over
- unvaccinated First Nation, Inuit and Métis individuals aged 50 and over
- unvaccinated individuals aged 50 and over with one or more risk factors
Paxlovid anti-viral treatment Treatment with Paxlovid must begin within five days of symptom onset to be effective. A full course of treatment is three pills twice daily for five days in a row.
The hospital stresses that Paxlovid is not a replacement for vaccination. This anti-viral treatment is intended for those who are at higher risk of severe outcomes that may lead to hospitalization.
Find full details on the hospitals website.
